Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Lexeo Therapeutics, Inc. (LXEO) had Consolidated Net Income/Loss of $-20.20M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-20.20M |
|
-- |
|
-- |
|
$22.33M |
|
$-22.33M |
|
$2.14M |
|
$-20.20M |
|
$-20.20M |
|
$-20.20M |
|
$-20.20M |
|
|
Consolidated Net Income/Loss |
$-20.20M |
$-20.20M |
|
$-22.33M |
|
$-22.30M |
|
81.18M |
|
81.18M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$200.86M |
|
$1.10M |
|
$49.49M |
|
$250.36M |
|
$14.19M |
|
$0.20M |
|
$4.67M |
|
$18.86M |
|
$231.50M |
|
$231.50M |
|
$231.50M |
|
74.09M |
|
| Cash Flow Statement Financials | |
$-21.14M |
|
$27.46M |
|
$2.45M |
|
$66.25M |
|
$75.02M |
|
$8.77M |
|
$2.75M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.16 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-21.18M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-8.72% |
|
-8.72% |
|
-8.07% |
|
-8.72% |
|
$3.12 |
|
$-0.26 |
|
$-0.26 |
|